Industries > Pharma > Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029

Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

PUBLISHED: 19 December 2018
PAGES: 160
PRODUCT CODE: PHA0349

Clear
WOOCS 2.2.1
DOWNLOAD SAMPLE
SKU: PHA0349 Categories: , , Tag:

The global asthma & COPD therapies market was valued at $36.21bn in 2018 and is projected to grow to $47bn by 2029.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 160-page report you will receive 86 charts– all unavailable elsewhere.

The 160-page report provides clear detailed insight into the Top 20 asthma & COPD companies. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Asthma & COPD Therapies Market forecasts from 2019-2029

• Profiles of the leading 20 asthma & COPD companies:
• Aerocrine (Circassia)
• ALK-Abello A/S
• Amphastar Pharmaceuticals, Inc.
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici
• Cipla
• GlaxoSmithKline
• Lallemand Pharma International
• Merck
• MundiPharma
• Novartis
• Pulmatrix
• Roche
• Sanofi/Regeneron
• Sunovion
• Teva
• Theravance Biopharma|Mylan Inc.
• Vectura Group plc
• Verona Pharma plc

Top 20 Asthma & COPD Companies 2019-2029

• The content of each profile differs, depending on the organization. In general, a profile gives the following information:
• An overview and analysis of the company
• A portfolio of the company’s marketed product and product pipeline
• Financial Information
• Revenue forecast from 2019-2029
• Recent developments
• Future Outlook

• This report discusses factors that drive and restrain the asthma and COPD market.

Visiongain’s study is intended for anyone requiring commercial analyses for the top 20 asthma & COPD therapies companies. You find data, trends and predictions.

Buy our report today Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029: Company Overview, Marketed Products, Product Pipeline, Revenues, Forecast

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

1 Report Overview
1.1 Global Asthma & COPD Companies Market Overview
1.2 Global Asthma & COPD Companies Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Key Questions Answered by this Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain

2 Introduction to Asthma & COPD Therapies
2.1 COPD Overview
2.1.1 Chronic Obstructive Pulmonary Disease Medications
2.2 Asthma Overview
2.2.1 Desirable inhaler characteristics for treating asthma
2.3 Asthma & COPD Respiratory Inhalers Overview
2.3.1 Nebulizers
2.3.2 Metered Dose Inhaler
2.3.3 Breath-Actuated Pressurised Metered-Dose Inhalers
2.3.4 Pressurised Metered-Dose Inhalers Plus Spacer Devices
2.3.5 Dry powder inhalers (DPIs)
2.3.6 Soft Mist Inhalers
2.4 Asthma & COPD Therapies – Realising Their Potential, Market Drivers
2.4.1 Combination Therapies - Asthma & COPD Products
2.4.2 Triple Combination – Asthma & COPD Products
2.4.3 Opportunities in Telehealth
2.5 Market Restraints
2.6 Asthma & COPD Products: Trends and Developments
2.6.1 E-Technology in Asthma and COPD

3 Leading Asthma & COPD Companies: Overview, 2018
3.1 The Global Asthma & COPD Companies Market In 2018
3.2 Leading Companies in the Asthma & COPD Market, 2018
3.3 How Will Leading Companies’ Market Shares Change to 2029?

4 Leading Asthma & COPD Companies Worldwide, 2018

4.1 Astrazeneca – Company Overview & Analysis
4.1.1 AstraZeneca Marketed Asthma & COPD products
4.1.2 AstraZeneca, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.1.3 AstraZeneca -Asthma & COPD Market Forecast, 2018-2029
4.2 GlaxoSmithKline – Company Overview & Analysis
4.2.1 GlaxoSmithKline Marketed Asthma & COPD products
4.2.2 GlaxoSmithKline, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.2.3 GlaxoSmithKline -Asthma & COPD Market Forecast, 2018-2029
4.3 Boehringer Ingelheim – Company Overview & Analysis
4.3.1 Boehringer Ingelheim Marketed Asthma & COPD products
4.3.2 Boehringer Ingelheim, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.3.3 Boehringer Ingelheim -Asthma & COPD Market Forecast, 2018-2029
4.4 Teva – Company Overview & Analysis
4.4.1 Teva Marketed Asthma & COPD products
4.4.2 Teva, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.4.3 Teva -Asthma & COPD Market Forecast, 2018-2029
4.5 Merck – Company Overview & Analysis
4.5.1 Merck Marketed Asthma & COPD products
4.5.2 Merck, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.5.3 Merck -Asthma & COPD Market Forecast, 2018-2029
4.6 Roche – Company Overview & Analysis
4.6.1 Roche Marketed Asthma & COPD products
4.6.2 Roche, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.6.3 Roche -Asthma & COPD Market Forecast, 2018-2029
4.7 Novartis – Company Overview & Analysis
4.7.1 Novartis Marketed Asthma & COPD products
4.7.2 Novartis, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.7.3 Novartis -Asthma & COPD Market Forecast, 2018-2029
4.8 Regeneron Pharmaceuticals (Sanofi)– Company Overview & ANALYSIS
4.8.1 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products- R&D Pipeline & Future Outlook
4.8.2 Regeneron Pharmaceuticals (Sanofi) -Asthma & COPD Market Forecast, 2018-2029
4.9 Mundipharma – Company Overview & Analysis
4.9.1 Mundipharma Marketed Asthma & COPD products
4.9.2 Mundipharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.10 Theravance Biopharma – Company Overview & Analysis
4.10.1 Theravance Biopharma Marketed Asthma & COPD products
4.10.2 Theravance Biopharma, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.11 Amphastar Pharmaceuticals – Company Overview & Analysis
4.11.1 Amphastar Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.12 Cipla– Company Overview & Analysis
4.12.1 Cipla Marketed Asthma & COPD products
4.13 Sunovion Pharmaceuticals– Company Overview & Analysis
4.13.1 Sunovion Pharmaceuticals: Marketed Asthma & COPD products
4.13.2 Sunovion Pharmaceuticals, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.13.3 Sunovion -Asthma & COPD Market Forecast, 2018-2029
4.14 Aerocrine (Circassia)– Company Overview & Analysis
4.14.1 Circassia Marketed Asthma & COPD products
4.14.2 Circassia, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.14.3 Circassia -Asthma & COPD Market Forecast, 2018-2029
4.15 Vectura Group – Company Overview & Analysis
4.15.1 Vectura Group Marketed Asthma & COPD products
4.15.2 Vectura Group, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.15.3 Vectura Group -Asthma & COPD Market Forecast, 2018-2029
4.16 Lallemand Pharma Ag– Company Overview & Analysis
4.16.1 Lallemand Pharma AG Marketed Asthma & COPD products
4.16.2 Lallemand Pharma AG, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.16.3 Lallemand Pharma -Asthma & COPD Market Forecast, 2018-2029
4.17 Chiesi Farmaceutici S.P.A. – Company Overview & Analysis
4.17.1 Chiesi Farmaceutici S.p.A Marketed Asthma & COPD Products
4.17.2 Chiesi Farmaceutici, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.17.3 Chiesi Farmaceutici: -Asthma & COPD Market Forecast, 2018-2029
4.18 Pulmatrix: Company Overview & Analysis
4.18.1 Pulmatrix, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.19 Verona Pharma Plc– Company Overview & Analysis
4.19.1 Verona Pharma plc, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.19.2 Verona Pharma plc -Asthma & COPD Market Forecast, 2018-2029
4.20 Alk-Abelló A/S– Company Overview & Analysis
4.20.1 ALK-Abelló A/S Marketed Asthma & COPD Products
4.20.2 ALK-Abelló A/S, Asthma & COPD Products- R&D Pipeline & Future Outlook
4.20.3 ALK-Abelló A/S -Asthma & COPD Market Forecast, 2018-2029

5 Conclusions
5.1 Asthma & COPD Products: A Maturing Market
5.2 The Global Asthma & COPD Companies Market In 2019
5.3 Leading Asthma & COPD Companies
5.4 Global Asthma & COPD Products Market Forecast 2019-2029
5.5 The Future of The Asthma & COPD Products Market
5.5.1 Growth in Anti-Inflammatory and Combination Drugs
5.5.2 Personalised Medicine
5.5.3 Unmet Needs in Asthma and COPD
5.6 Strategies for Growth in 2018-2029

Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Visiongain Report Evaluation Form

List of Tables
Table 2.1 Advantages and Disadvantages of the Main Types of Asthma Inhalers
Table 2.2 E-Technology Based Inhalers
Table 3.1 Global Market Forecast: Revenues ($bn), AGR (%) By Leading Companies, 2018-2029
Table 3.2 Leading Companies in Asthma & COPD diseases
Table 3.3 Leading Asthma & COPD Companies: Revenues ($bn) and Market Shares (%), 2019 And 2029
Table 4.1 Astrazeneca: Company Overview
Table 4.2 Astrazeneca: Products Portfolio
Table 4.3 Astrazeneca: Products Pipeline Portfolio
Table 4.4 Astrazeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.5 Glaxosmithkline: Company Overview
Table 4.6 Glaxosmithkline: Products Portfolio
Table 4.7 Glaxosmithkline: Products Pipeline Portfolio
Table 4.8 Glaxosmithkline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.9 Boehringer Ingelheim: Company Overview
Table 4.10 Boehringer Ingelheim: Products Portfolio
Table 4.11 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.12 Teva: Company Overview
Table 4.13 Teva: Products Portfolio
Table 4.14 Teva: Products Pipeline Portfolio
Table 4.15 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.16 Merck: Company Overview
Table 4.17 Merck: Products Portfolio
Table 4.18 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.19 Roche: Company Overview
Table 4.20 Roche: Products Portfolio
Table 4.21 Roche: Products Pipeline Portfolio
Table 4.22 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.23 Novartis: Company Overview
Table 4.24 Novartis: Products Portfolio
Table 4.25 Novartis: Products Pipeline Portfolio
Table 4.26 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.27 Regeneron Pharmaceuticals (Sanofi): Company Overview
Table 4.28 Regeneron Pharmaceuticals (Sanofi): Product Pipeline Portfolio
Table 4.29 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.30 Mundipharma: Company Overview
Table 4.31 Mundipharma: Products Portfolio
Table 4.32 Mundipharma: Products Pipeline Portfolio
Table 4.33 Theravance Biopharma: Company Overview
Table 4.34 Theravance Biopharma: Products Portfolio
Table 4.35 Theravance Biopharma: Products Pipeline Portfolio
Table 4.36 Amphastar Pharmaceuticals: Company Overview
Table 4.37 Amphastar Pharmaceuticals: Products Pipeline Portfolio
Table 4.38 Cipla: Company Overview
Table 4.39 Cipla: Products Portfolio
Table 4.40 Sunovion Pharmaceuticals: Company Overview
Table 4.41 Sunovion Pharmaceuticals: Products Portfolio
Table 4.42 Sunovion: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.43 Circassia: Company Overview
Table 4.44 Circassia: Products Portfolio
Table 4.45 Circassia: Products Pipeline Portfolio
Table 4.46 Vectura Group: Company Overview
Table 4.47 Vectura Group: Products Portfolio
Table 4.48 Vectura Group: Products Pipeline Portfolio
Table 4.49 Lallemand Pharma AG: Company Overview
Table 4.50 Lallemand Pharma AG: Products Portfolio
Table 4.51 Lallemand Pharma AG: Products Pipeline Portfolio
Table 4.52 Chiesi Farmaceutici S.P.A: Company Overview
Table 4.53 Chiesi Farmaceutici S.P.A: Products Portfolio
Table 4.54 Chiesi Farmaceutici S.P.A: Products Pipeline Portfolio
Table 4.55 Chiesi Farmaceutici S.P.A: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), CAGR (%), 2018-2029
Table 4.56 Pulmatrix: Company Overview
Table 4.57 Pulmatrix: Products Pipeline Portfolio
Table 4.58 Verona Pharma Plc: Company Overview
Table 4.59 Verona Pharma Plc: Products Pipeline Portfolio
Table 4.60 Alk-Abelló A/S: Company Overview
Table 4.61 Alk-Abelló A/S Products Portfolio
Table 4.62 Alk-Abelló A/S: Products Pipeline Portfolio

List of Figures
Figure 1.1 Global Asthma & COPD Companies Market Segmentation Overview, 2019
Figure 2.1 Stepwise Approach to Treatment of COPD
Figure 2.2 Stepwise Approach to Treatment of Asthma
Figure 3.1 Global: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 3.2 Leading Asthma & COPD Drug Manufacturers: Revenue ($bn), 2019
Figure 3.3 Leading Asthma & COPD Drug Manufacturers: Market Share (%), 2019
Figure 3.4 Leading Asthma & COPD Companies: Revenues ($bn), 2029
Figure 3.5 Leading Asthma & COPD Companies: Market Shares (%), 2029
Figure 4.1 AstraZeneca: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.2 GlaxoSmithKline: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.3 Boehringer Ingelheim: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.4 Teva: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.5 Merck: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.6 Roche: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.7 Novartis: Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.8 Regeneron Pharmaceuticals (Sanofi): Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.9 Sunovion Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 4.10 Chiesi Farmaceutici Asthma & COPD Products Forecast: Revenue ($bn), AGR (%), 2018-2029
Figure 5.1 World Asthma & COPD Products Market Forecast: Revenues ($bn), 2019-2029
Aerocrine (Circassia)
ALK-Abello A/S
American College of Chest Physicians (ACCP)
Amphastar Pharmaceuticals, Inc.
AstraZeneca
Boehringer Ingelheim
Chiesi Farmaceutici
Ciba-Geigy
Cipla
Committee for Medicinal Products for Human Use (CHMP)
Dainippon Sumitomo Pharma America, Inc.
Dermira Inc.
European Medicines Agency (EMA)
European Respiratory Society (ERS)
GlaxoSmithKline (GSK)
Glenmark
Hikma
Innovata plc
Innoviva, Inc.
Japanese Ministry of Health, Labour and Welfare
Lallemand Pharma International
Medicines and Healthcare products Regulatory Agency (MHRA)
Merck
Monitored Therapeutics, Inc. (MTI)
MundiPharma
Mylan
National Institute for Health and Care Excellence (NICE)
Novartis
Pulmatrix
Regeneron
Roche
Sandoz
Sanofi
Sepracor Inc.
Sorrento
Sunovion
Teva
Theravance Biopharma|Mylan Inc.
Torii
Vectura Group plc
Verona Pharma plc

Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


Download sample pages

Complete the form below to download your free sample pages for Pharma Leader Series: Top 20 Asthma & COPD Companies 2019-2029


facebookWin a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.

Click here to ‘Like’ our Facebook page https://www.facebook.com/V.G.Pharma/

Would you like a free report overview of the report of your choice?

If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com

Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Would you like to get the latest Visiongain pharma reports catalogue?

What are the dynamic growth sectors? where are the regional business opportunities?

Which technologies will prevail and who are the leading companies succeeding in these sectors and why?

If you want definitive answers to business critical questions, discover Visiongain’s full range of business intelligence reports.

If so, please email Sara Peerun on sara.peerun@visiongain.com or call her today on +44 (0) 20 7549 9987

  • Human Microbiome Therapeutics Market 2019-2029
  • Top 20 Urology Companies 2019
  • Global Antidepressant and Anti-Anxiety Drugs Market Forecasts 2019-2029
  • The Top 100 In-Vitro Diagnostics Companies to Watch 2019
  • Global Hypertension Drugs Market 2019-2029
  • The Next Generation Sequencing Market 2019-2029
  • Lyophilisation for Pharmaceuticals: Products and Services 2019-2029
  • Top 25 In Vitro Diagnostics (IVD) Companies 2019
  • Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2019-2029
  • Global Biomarkets and Technologies Market 2019-2029
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Kuwait Pharmaceutical Association
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Generic Medicines Association
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Latest Pharma news

“In 2017, the Top 5 Vaccines Manufacturers held 76% of the Global Vaccines Market” says new Visiongain report

Progress in R&D in the therapeutic vaccine field will yield revolutionary results and answer unmet medical needs.

12 February 2019

READ

“Translational Regenerative Medicine market set to grow to $76bn by 2023” says new Visiongain report

Regenerative medicine has become an area of competition between many national governments, particularly in Asia-Pacific.

07 February 2019

READ

“Global Pre-Filled Syringes market set to grow to $19bn by 2024” says new Visiongain report

The market is expected to grow strongly driven by numerous trends in the overall pharmaceutical market, such as more self-administration of medicines, the development of biological drugs and biosimilars, and the increasing burden of chronic diseases such as diabetes and high cholesterol.

31 January 2019

READ

“30% of the Top Generic Drug Producers are in the ROW region” says new Visiongain report

This report ranks the world’s top 50 generic drug manufacturers according to their generic drug revenues in 2017.

31 January 2019

READ

Categories

Category